{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:52:52Z","timestamp":1782989572128,"version":"3.54.5"},"reference-count":21,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0060","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:13:25Z","timestamp":1782987205000},"source":"Crossref","is-referenced-by-count":0,"title":["Ocular side effects of antibody\u2013drug conjugates for cancer treatment"],"prefix":"10.3238","author":[{"given":"Florian","family":"Heitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Scheider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Harter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Groeben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"10.3238\/arztebl.m2026.0060_ref1","unstructured":"Robert Koch-Institut: Krebs in Deutschland 2021\u20132023. 2025, Robert Koch-Institut. www.gbe.rki.de\/SharedDocs\/Publikationen\/DE\/RKI-2025-Krebs-in-Deutschland.html (last accessed on 16 April 2026)."},{"key":"10.3238\/arztebl.m2026.0060_ref2","unstructured":"Ronckers C, Spix C, Tr\u00fcbenbach C, et al.: Krebs in Deutschland f\u00fcr 2019\/2020. Robert Koch-Institut 2023; p. 164."},{"key":"10.3238\/arztebl.m2026.0060_ref3","doi-asserted-by":"crossref","unstructured":"Lordick F, Merz M, B\u00fcch E, Aigner A: Antibody-drug conjugates as a targeted therapeutic approach across entities in oncology. Dtsch Arztebl Int 2023; 120: 329\u201336","DOI":"10.3238\/arztebl.m2023.0093"},{"key":"10.3238\/arztebl.m2026.0060_ref4","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Beksac M, Pour L, et al.: Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma. N Engl J Med 2024; 391: 408\u201321","DOI":"10.1056\/NEJMoa2403407"},{"key":"10.3238\/arztebl.m2026.0060_ref5","doi-asserted-by":"crossref","unstructured":"Hsu ST, Ponugoti A, Deaner JD, Vajzovic L: Update on retinal drug toxicities. Curr Ophthalmol Rep 2021; 9: 168\u201377","DOI":"10.1007\/s40135-021-00277-x"},{"key":"10.3238\/arztebl.m2026.0060_ref6","doi-asserted-by":"crossref","unstructured":"Lindgren ES, Yan R, Cil O, et al.: Incidence and mitigation of corneal pseudomicrocysts induced by antibody-drug conjugates (ADCs). Curr Ophthalmol Rep 2024; 12: 13\u201322","DOI":"10.1007\/s40135-024-00322-5"},{"key":"10.3238\/arztebl.m2026.0060_ref7","doi-asserted-by":"crossref","unstructured":"Matulonis UA, Birrer MJ, O\u2018Malley DM, et al.: Evaluation of prophylactic corticosteroid eye drop use in the management of corneal abnormalities induced by the antibody-drug conjugate mirvetuximab soravtansine. Clin Cancer Res 2019; 25: 1727\u201336","DOI":"10.1158\/1078-0432.CCR-18-2474"},{"key":"10.3238\/arztebl.m2026.0060_ref8","doi-asserted-by":"crossref","unstructured":"Kim SK, Ursell P, Coleman RL, Monk BJ, Vergote I: Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol 2022; 165: 385\u201392","DOI":"10.1016\/j.ygyno.2022.02.010"},{"key":"10.3238\/arztebl.m2026.0060_ref9","doi-asserted-by":"crossref","unstructured":"Donaghy H: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs 2016; 8: 659\u201371","DOI":"10.1080\/19420862.2016.1156829"},{"key":"10.3238\/arztebl.m2026.0060_ref10","doi-asserted-by":"crossref","unstructured":"Zhao H, Atkinson J, Gulesserian S, et al.: Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res 2018; 78: 2115\u201326","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"10.3238\/arztebl.m2026.0060_ref11","doi-asserted-by":"crossref","unstructured":"Hungria V, Robak P, Hus M, et al.: Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 2024; 391: 393\u2013407","DOI":"10.1056\/NEJMoa2405090"},{"key":"10.3238\/arztebl.m2026.0060_ref12","doi-asserted-by":"crossref","unstructured":"Moore KN, Angelergues A, Konecny GE, et al.: Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med 2023; 389: 2162\u201374","DOI":"10.1056\/NEJMoa2309169"},{"key":"10.3238\/arztebl.m2026.0060_ref13","doi-asserted-by":"crossref","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, et al.: Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 2024; 391: 44\u201355","DOI":"10.1056\/NEJMoa2313811"},{"key":"10.3238\/arztebl.m2026.0060_ref14","doi-asserted-by":"crossref","unstructured":"Bardia A, Krop IE, Kogawa T, et al.: Datopotamab deruxtecan in advanced or metastatic HR+\/HER2\u2013 and triple-negative breast cancer: Results from the phase I TROPION-PanTumor01 study. J Clin Oncol 2024; 42: 2281\u201394","DOI":"10.1200\/JCO.23.01909"},{"key":"10.3238\/arztebl.m2026.0060_ref15","doi-asserted-by":"crossref","unstructured":"Gilbert L, Oaknin A, Matulonis UA, et al.: Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol 2023; 170: 241\u20137","DOI":"10.1016\/j.ygyno.2023.01.020"},{"key":"10.3238\/arztebl.m2026.0060_ref16","doi-asserted-by":"crossref","unstructured":"Hong DS, Concin N, Vergote I, et al.: Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res 2020; 26: 1220\u20138","DOI":"10.1158\/1078-0432.CCR-19-2962"},{"key":"10.3238\/arztebl.m2026.0060_ref17","doi-asserted-by":"crossref","unstructured":"Pistilli B, Jhaveri K, Im SA, et al.: Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: Final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol 2025: S0923\u20137534(25)06337\u20139. doi: 10.1016\/j.annonc.2025.12.017. Online ahead of print","DOI":"10.1016\/j.annonc.2025.12.017"},{"key":"10.3238\/arztebl.m2026.0060_ref18","unstructured":"Abbvie, www.elaherehcp.com\/eye-care (last accessed on 5 May 2026)"},{"key":"10.3238\/arztebl.m2026.0060_ref19","unstructured":"Genmab, www.tivdakhcp.com\/eye-care (last accessed on 5 May 2026)"},{"key":"10.3238\/arztebl.m2026.0060_ref20","doi-asserted-by":"crossref","unstructured":"Lent-Schochet D, Tauber S, Seagrave Z, Paley GL, Farooq AV: Ocular surface disease related to tisotumab vedotin-tftv. Gynecol Oncol Rep 2025; 57: 101676","DOI":"10.1016\/j.gore.2025.101676"},{"key":"10.3238\/arztebl.m2026.0060_ref21","doi-asserted-by":"crossref","unstructured":"Farooq AV, Esposti SD, Popat R, et al.: Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther 2020; 9: 889\u2013911","DOI":"10.1007\/s40123-020-00280-8"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:18:30Z","timestamp":1782987510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":21,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0060","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}